Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization

• Conditions: Lung Cancer and Idiopathic Pulmonary Fibrosis

• Registration Number: NCT03486262
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

Retrospective inclusion of lung cancers developed in a context of idiopathic pulmonary fibrosis, diagnosed and / or treated in participating centers. The cases are recovered retrospectively from the records of the pulmonology and pathology departments of our various partners.

Detailed Description

Primary objective:

Characterize altered molecular pathways in lung cancer in patients with IPF versus lung cancer in non-IPF patients.

Secondary objectives:

Identify specific therapeutic targets Describe a cohort of lung cancers on IPF (clinical / radiological and pathological data) To study the relationship between neoplastic / preneoplastic lesions and pulmonary parenchyma reshaped by fibrosis.

Study Timeline

• Status Verified: 2018-02
• Study Start: 2018-02-01
• Study First Submitted: 2018-03-27
• Study First Submitted QC: 2018-03-27
• Study First Posted: 2018-04-03
• Last Update Submitted: 2018-10-10
• Last Update Posted: 2018-10-11
• Primary Completion: 2020-02
• Study Completion: 2020-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Lung carcinoma
• Idiopathic pulmonary fibrosis

Exclusion Criteria

• No tumor sample available

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Molecular profile of IPF-associated lung carcinomas	1 month / 8 samples	Next generation sequencing of carcinomas with Ion S5 XL sequencer and Oncomine™ Comprehensive Panel

Secondary Outcome Measures

Name	Time	Method
Pathological characterization of lung carcinomas	1 month / 8 samples	Histological classification of carcinomas and immunohistochemistry with lineage markers

Trial Locations

Locations (1)

Hopital BICHAT-CLAUDE BERNARD; 🇫🇷 Paris, France